| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Annelies Van Rie | Q42552797 |
| Amitabh B Suthar | Q58824181 | ||
| P2093 | author name string | Jonathan Mermin | |
| Reuben Granich | |||
| P2860 | cites work | The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration | Q21092360 |
| Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV | Q24247929 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared | Q28473120 | ||
| Rapid Implementation of an Integrated Large-Scale HIV Counseling and Testing, Malaria, and Diarrhea Prevention Campaign in Rural Kenya | Q28749556 | ||
| Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean | Q28749991 | ||
| Primary prevention with cotrimoxazole for HIV-1-infected adults: results of the pilot study in Dakar, Senegal | Q32165540 | ||
| Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa | Q33745099 | ||
| Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. | Q33793347 | ||
| Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review | Q33979497 | ||
| Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. | Q34166980 | ||
| Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa | Q34209707 | ||
| Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia | Q34257244 | ||
| Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America | Q34974892 | ||
| Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study | Q35166201 | ||
| Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study | Q35606796 | ||
| Implementation of free cotrimoxazole prophylaxis improves clinic retention among antiretroviral therapy-ineligible clients in Kenya | Q36058019 | ||
| Predictors of adherence to antiretroviral therapy in rural Zambia. | Q37061960 | ||
| Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial | Q37131431 | ||
| Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa | Q37265947 | ||
| Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India | Q37562506 | ||
| Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort | Q38872771 | ||
| Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort | Q38873960 | ||
| Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among Ugandan adults | Q38874698 | ||
| Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study | Q38876606 | ||
| Antiretroviral therapy in a thousand patients with AIDS in Haiti | Q39447948 | ||
| The benefit of supplementary feeding for wasted Malawian adults initiating ART. | Q43063695 | ||
| Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group | Q43836224 | ||
| Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? | Q44434854 | ||
| National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes | Q46119003 | ||
| Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries | Q46391119 | ||
| Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia | Q46769635 | ||
| Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia | Q56839332 | ||
| Effectiveness of Antiretroviral Treatment in a South African Program A Cohort Study | Q57343454 | ||
| Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi | Q62487042 | ||
| Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial | Q64131962 | ||
| Treatment 2.0: catalysing the next phase of scale-up | Q83481240 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systematic review | Q1504425 |
| meta-analysis | Q815382 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 128C-138C | |
| P577 | publication date | 2011-10-24 | |
| P1433 | published in | Bulletin of the World Health Organization | Q2928049 |
| P1476 | title | Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis | |
| P478 | volume | 90 |
| Q53679268 | A man with unsuspected marine eosinophilic gastritis. |
| Q34687538 | A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa |
| Q28084544 | Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review |
| Q38864845 | Birth Weight and Lung Function in Adulthood: A Systematic Review and Meta-analysis |
| Q35053423 | Co-detection of Panton-Valentine leukocidin encoding genes and cotrimoxazole resistance in Staphylococcus aureus in Gabon: implications for HIV-patients' care |
| Q38596372 | Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis |
| Q28552031 | Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial |
| Q33926897 | Cotrimoxazole and neonatal kernicterus: a review |
| Q35211308 | Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China |
| Q41916961 | Cotrimoxazole-induced hypoglycaemia in a patient with churg-strauss syndrome |
| Q40144262 | Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study |
| Q36380594 | Effect of increased ART-CPT uptake on tuberculosis outcomes and associated factors, Burundi, 2009-2013. |
| Q46158096 | Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial |
| Q40542672 | Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. |
| Q36901503 | Extensive antibiotic prescription rate among hospitalized patients in Uganda: but with frequent missed-dose days |
| Q38217764 | Global Policy Review of Recommendations on Cotrimoxazole Prophylaxis among People Living with HIV. |
| Q26824501 | HIV and tuberculosis--science and implementation to turn the tide and reduce deaths |
| Q36480371 | Improved survival with co-trimoxazole prophylaxis among people living with HIV/AIDS who initiated antiretroviral treatment in Henan Province, China |
| Q38221645 | Management of BU-HIV co-infection |
| Q34497311 | Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia |
| Q40578494 | Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. |
| Q37617342 | Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort |
| Q38942938 | Quantification of co-trimoxazole in serum and plasma using MS/MS. |
| Q39001817 | Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. |
| Q34626712 | Risk of healthcare associated infections in HIV positive patients |
| Q35090697 | Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis |
| Q35973095 | Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design |
| Q38975088 | Survival of HIV-1 vertically infected children |
| Q38330997 | The expanding role of co-trimoxazole in developing countries |
| Q38281773 | The future role of CD4 cell count for monitoring antiretroviral therapy |
| Q64067248 | The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis |
| Q36123049 | Trends and Predictors of Mortality Among HIV Positive Patients in the Era of Highly Active Antiretroviral Therapy in Uganda |
| Q38750914 | Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment - 10 Countries, 2004-2015. |
Search more.